QDVG:F:F-iShares S&P 500 Health Care Sector UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 10.426

Change

-0.04 (-0.36)%

Market Cap

N/A

Volume

N/A

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-30 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

+0.20 (+0.73%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

+0.10 (+0.18%)

USD 116.19B
SXR8:F iShares Core S&P 500 UCITS ETF..

+1.50 (+0.25%)

USD 109.51B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

+0.42 (+0.74%)

USD 98.97B
XDNY:F Xtrackers MSCI Japan ESG Scree..

N/A

USD 63.27B
SXRZ:F iShares VII PLC - iShares Nikk..

N/A

USD 52.42B
VUSA:F Vanguard Funds Public Limited ..

+0.35 (+0.32%)

USD 51.63B
VUAA:F Vanguard S&P 500 UCITS Acc

+0.26 (+0.24%)

USD 51.63B
XJSE:F Xtrackers II - Japan Governmen..

+0.12 (+1.64%)

USD 38.52B
0ZC:F Zscaler Inc

+2.62 (+1.50%)

USD 37.92B

ETFs Containing QDVG:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.75% 53% F 59% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.75% 49% F 51% F
Trailing 12 Months  
Capital Gain 8.75% 53% F 59% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.75% 49% F 51% F
Trailing 5 Years  
Capital Gain 54.16% 79% B- 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 54.16% 79% B- 57% F
Average Annual (5 Year Horizon)  
Capital Gain 12.64% 78% C+ 71% C-
Dividend Return 12.64% 76% C+ 63% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 11.00% 63% D 88% B+
Risk Adjusted Return 114.92% 98% N/A 97% N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike